BDX · News · 20260807N

Licensing / Collaboration Deals

BECTON DICKINSON & CO · 2026-08-07 · Importance 31 · Surprise 42

BD partnered with EMS to launch a semaglutide therapy in Brazil using BD’s Vystra injection pen. The initiative expands BD’s drug-delivery-device presence in Brazil and links its pen technology to the country’s GLP-1 treatment market. The reporting did not disclose the partnership’s revenue contribution, investment amount, or launch timetable beyond describing it as a recent partnership.

Key facts

• Company expanded its GLP-1 partnerships, as noted in Q3 commentary. source